Study identifier:D8450R00003
ClinicalTrials.gov identifier:NCT06465810
EudraCT identifier:N/A
CTIS identifier:N/A
A Non-interventional, Prospective, Multi-country Study Collecting Real-world Data on the Characteristics, Treatment Patterns, and Outcomes of Patients with Transthyretin (ATTR) Amyloidosis
Transthyretin Amyloidosis
Phase 4
No
Treatment of transthyretin (ATTR) amyloidosis in observational study setting
All
1600
Observational
18 Years - 130 Years
Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verified 01 Sept 2024 by AstraZeneca
AstraZeneca
ICON plc
No locations available
Arms | Assigned Interventions |
---|---|
ATTR cardiomyopathy (ATTR-CM) Patients with ATTR-CM at enrollment | Drug: Treatment of transthyretin (ATTR) amyloidosis in observational study setting Data will be collected on patients with ATTR amyloidosis in a real-world setting |
Hereditary polyneuropathy (ATTRv-PN) Patients with ATTRv-PN at enrollment | Drug: Treatment of transthyretin (ATTR) amyloidosis in observational study setting Data will be collected on patients with ATTR amyloidosis in a real-world setting |
ATTR-Mixed Patients with a mixed ATTR amyloidosis phenotype | Drug: Treatment of transthyretin (ATTR) amyloidosis in observational study setting Data will be collected on patients with ATTR amyloidosis in a real-world setting |